This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Dayspring Pharma CG2001 Phase II Results
Tech clinical trial results

Dayspring Pharma CG2001 Phase II Results

Analysis based on 9 articles · First reported Jun 08, 2026 · Last updated Jun 08, 2026

Sentiment
60
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive Phase II clinical trial results for CG2001 by Dayspring Pharma are expected to positively impact the company's valuation and future investment prospects. This development could also signal increased competition and innovation within the dermatology and hair health market, potentially affecting other companies in the sector.

Biotechnology Pharmaceuticals
Event Summary

Dayspring Pharma, a clinical-stage biotechnology company, announced positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001 for the treatment of male androgenetic alopecia. The results were presented by Professor Cheng Zhou at the 14th World Congress for Hair Research in Seoul, South Korea. The study met its primary endpoint, showing a statistically significant improvement in Target Area Hair Count (TAHC) for the CG2001 (5% Minoxidil and 0.075% Finasteride) twice-daily group compared to placebo. Favorable safety and tolerability were also observed. Baohui Yu, CEO of Dayspring Pharma, expressed encouragement, noting CG2001's potential as a differentiated treatment option. Dayspring Pharma is now engaging with regulatory authorities to plan the next phase of clinical development for CG2001, a topical combination of minoxidil and finasteride.

Entities Involved
priv
Dayspring Pharma
Dayspring Pharma announced positive topline results from its Phase II clinical trial of CG2001, supporting its potential as a differentiated treatment option for androgenetic alopecia and its continued clinical development. This positive outcome enhances the company's prospects and product pipeline.
Importance 100.0 Sentiment 70.0
per
Cheng Zhou
Professor Cheng Zhou presented the positive topline results of the CG2001 trial at the 14th World Congress for Hair Research, lending academic credibility to the findings.
Importance 30.0 Sentiment 20.0
per
Baohui Yu
Baohui Yu, CEO of Dayspring Pharma, expressed encouragement regarding the Phase II results, highlighting CG2001's potential and the company's commitment to its clinical development.
Importance 30.0 Sentiment 20.0
oth
Peking University People s Hospital
Professor Cheng Zhou, Director of the Department of Dermatology at Peking University People s Hospital, presented the trial results, associating the institution with the research.
Importance 10.0 Sentiment 10.0
cnt
South Korea
South Korea was the location for the 14th World Congress for Hair Research where the trial results were presented.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.